Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease (EVINCI)

Evaluation of Integrated Cardiac Imaging for the Detection and Characterization of Ischemic Heart Disease

Main purpose of the study:

To comparatively assess the diagnostic performance of non invasive anatomical and functional imaging modalities to detect significant obstructive coronary artery disease as demonstrated at invasive coronary angiography and functional evaluation of coronary lesions (fractional flow reserve).

Study Overview

• Status: Completed
• Conditions: Ischemic Heart Disease
• Intervention / Treatment: Other: Non invasive cardiac imaging

Detailed Description

Objectives of the study

1. To test the accuracy of anatomical and functional non-invasive cardiac imaging in the diagnosis of IHD. To this purpose the "anatomical" information provided by CTA is obtained in every patient together with the "functional" information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction. Non-invasive results are tested against invasive reference standards. The latter consists of invasive coronary angiography integrated by invasive measurement of fractional flow reserve (to assess the hemodynamic relevance of intermediate coronary stenoses).
2. To test the accuracy of integrated models, including clinical variables, risk factors and circulating biomarkers, to predict significant obstructive coronary artery disease in patients with chronic angina-like symptoms. To correlate biohumoral profiles with the coronary anatomical-functional phenotype as obtained by non invasive imaging in the same patients. To reach these goals the clinical characterization of patients (collected before non-invasive imaging) and the laboratory characterization (that includes novel biomarkers of cardiovascular risk) are compared with patient characterization derived from non invasive "anatomic-functional" imaging and with invasive diagnosis of significantly obstructive coronary disease.
3. To develop an advanced clinical and imaging reporting tool in cardiology. An informatics platform is developed to synthetically and clearly present the integrated clinical and imaging diagnostic profile of individual patients. A multimodal imaging reporting tool is developed including tools for "image fusion" of different imaging modalities (CT, SPECT, PET, MRI).
4. To define the most cost-effective work-up for the diagnosis and characterization of IHD. To this purpose the costs and the procedural risks (including radiation exposure) of non-invasive and invasive diagnostic procedures are prospectively collected. Cost-benefit and cost-effectiveness analyses is conducted alongside the EVINCI-study clinical trial.

• Study Type: Interventional
• Enrollment (Actual): 697
• Phase: Phase 4

Contacts and Locations

Study Locations

• Finland
  • Turku, Finland
    • U.Turku
• France
  • Paris, France
    • APHP
• Germany
  • Goeppingen, Germany
    • KAE Goeppingen
  • Munich, Germany
    • TUM
• Italy
  • Genova, Italy
    • Unige
  • Naples, Italy
    • UniNA
  • Pisa, Italy
    • CNR
  • Pisa, Italy
    • FGM
  • Lucca
    • Viareggio, Lucca, Italy, 55100
      • Ospedale Versilia
• Netherlands
  • Leiden, Netherlands
    • LUMC
• Poland
  • Warsaw, Poland
    • NIC
• Spain
  • Barcelona, Spain
    • Huvhebron
  • Madrid, Spain
    • SERMAS
• Switzerland
  • Zurich, Switzerland
    • UZH
• United Kingdom
  • London, United Kingdom
    • QUEEN MARY Hospital London
  • London, United Kingdom
    • RBHT

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with intermediate (>20%, <90%) risk of IHD based on age,gender,symptoms and exercise stress test results

Exclusion Criteria:

• Age < 30 Yrs or > 75 yrs
• Pregnancy (suspected or ascertained)
• LV Dysfunction (LVEF < 35% by Echo or other method)
• Low (< =20%) or high (>=90%) probability of CAD
• Acute Coronary Syndrome
• Prolonged (> 20 minutes) chest pain
• De novo or accelerated angina
• Hemodynamic or electrical instability
• Recent ST-T segment or T wave changes of ischemic nature
• Acute myocardial infarction with or without ST segment elevation
• Elevated serum cardiac markers of necrosis
• Known diagnosis of CAD
• Previously known myocardial infarction
• Previous PCI
• Previous CABG
• Persistent atrial fibrillation or advanced AV Block
• Asthma or chronic treatment with aminophylline
• Recent (<6 months) cerebral ischemic attack
• Known significant carotid stenosis or vascular aneurisms
• Asthma or chronic treatment with aminophylline
• Active cancer
• Severe hypertension. Patients cannot withdraw therapy for 12 hours.
• Congenital heart disease
• Significant valvular disease
• Cardiomyopathy (e.g. DCM, HCM, ARVC, Amyloidosis)
• Inability to provide an informed consent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Non invasive cardiac imaging; Intervention: Non invasive cardiac imaging. 'Anatomical' information provided by CTCA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction.	Other: Non invasive cardiac imaging; Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement	The outcome measure is the number of participants who received the diagnosis of IHD at invasive coronary angiography coupled with FFR measurements (in case of intermediate coronary lesions).	3 months from enrollment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cost-benefit and Cost-effectiveness Analysis	Different non invasive imaging modalities are compared in terms of a cost-effectiveness analysis where costs include direct and indirect costs incurred as a consequence of the use of each modality or combination of modalities and effectiveness is the diagnostic accuracy with invasive diagnosis of IHD as end-point.	3 months

Collaborators and Investigators

• Sponsor: Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
• Collaborators: European Commission
• Investigators: Principal Investigator: Danilo Neglia, MD, PhD, Fondazione Toscana G. Monasterio, Pisa, Italy

Publications and helpful links

General Publications

• Caselli C, De Caterina R, Smit JM, Campolo J, El Mahdiui M, Ragusa R, Clemente A, Sampietro T, Clerico A, Liga R, Pelosi G, Rocchiccioli S, Parodi O, Scholte A, Knuuti J, Neglia D; EVINCI and SMARTool. Triglycerides and low HDL cholesterol predict coronary heart disease risk in patients with stable angina. Sci Rep. 2021 Oct 20;11(1):20714. doi: 10.1038/s41598-021-00020-3.
• Caselli C, Del Turco S, Ragusa R, Lorenzoni V, De Graaf M, Basta G, Scholte A, De Caterina R, Neglia D. Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovasc Diabetol. 2019 Oct 31;18(1):144. doi: 10.1186/s12933-019-0949-3.
• Carpeggiani C, Picano E, Brambilla M, Michelassi C, Knuuti J, Kauffman P, Underwood SR, Neglia D; EVINCI Study Investigators. Variability of radiation doses of cardiac diagnostic imaging tests: the RADIO-EVINCI study (RADIationdOse subproject of the EVINCI study). BMC Cardiovasc Disord. 2017 Feb 16;17(1):63. doi: 10.1186/s12872-017-0474-9.
• Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguade-Bruix S, Pizzi MN, Todiere G, Gimelli A, Schroeder S, Drosch T, Poddighe R, Casolo G, Anagnostopoulos C, Pugliese F, Rouzet F, Le Guludec D, Cappelli F, Valente S, Gensini GF, Zawaideh C, Capitanio S, Sambuceti G, Marsico F, Perrone Filardi P, Fernandez-Golfin C, Rincon LM, Graner FP, de Graaf MA, Fiechter M, Stehli J, Gaemperli O, Reyes E, Nkomo S, Maki M, Lorenzoni V, Turchetti G, Carpeggiani C, Marinelli M, Puzzuoli S, Mangione M, Marcheschi P, Mariani F, Giannessi D, Nekolla S, Lombardi M, Sicari R, Scholte AJ, Zamorano JL, Kaufmann PA, Underwood SR, Knuuti J; EVINCI Study Investigators. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imaging. 2015 Mar;8(3):e002179. doi: 10.1161/CIRCIMAGING.114.002179.

Helpful Links

• Related Info
• Related Info

Study record dates

Study Major Dates

• Study Start: February 1, 2009
• Primary Completion (Actual): July 1, 2010
• Study Completion (Actual): June 1, 2012

Study Registration Dates

• First Submitted: September 16, 2009
• First Submitted That Met QC Criteria: September 16, 2009
• First Posted (Estimate): September 17, 2009

Study Record Updates

• Last Update Posted (Estimate): July 21, 2014
• Last Update Submitted That Met QC Criteria: June 19, 2014
• Last Verified: June 1, 2014

More Information

Terms related to this study

• Keywords: PET; Echocardiography; SPECT; CMR; CAD; IHD; Non invasive imaging
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Heart Diseases; Coronary Artery Disease; Myocardial Ischemia; Ischemia
• Other Study ID Numbers: EVINCI; European Commission (Other Grant/Funding Number: Horizon EU Grant Agreement 101080323); FPVII grant 222915